$3.02
0.03991.34%
Last update: Nov 11, 10:31 AM
Nasus Pharma Ltd
NSRXAMEX
Nasus Pharma fell 60.7% from $7.59 to $2.99, behind the S&P 500's +9.7%. Its worst day was Mar 16 (−38.0%), and its low came Mar 30 at $2.01.
Nov 12, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Nasus Pharma shares rose 18.9%, while the S&P 500 rose 0.9%.
+18.9% · S&P 500 +0.9%
EPS of $-0.17 missed the $-0.14 estimate on $0.00 revenue.
−1.4% · S&P 500 −0.4%
Story events cover the past 12 months · Times ET
Nasus Pharma shares rose 18.0%, while the S&P 500 rose 0.7%.
+18.0% · S&P 500 +0.7%
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033).
−38.0%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 +1.0%
EPS of $-0.72 missed the $-0.19 estimate on $0.00 revenue.
+10.8% · S&P 500 +0.6%
Nasus Pharma shares rose 27.7%, while the S&P 500 fell 0.2%.
+27.7%, the year's best day · S&P 500 −0.2%
EPS of $-0.54 missed the $-0.20 estimate on $0.00 revenue.
+2.2% · S&P 500 −0.5%
Where it ended: a close of $2.98 on Nov 10, 2026. Up next: FY 2026 earnings on Feb 15, 2027 (EPS est. $-1.07).
Nothing in the past 12 months.
All NSRX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NSRX and SPY from Benzinga historical bars. Not investment advice.
